<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14979">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02911870</url>
  </required_header>
  <id_info>
    <org_study_id>NN9924-4247</org_study_id>
    <secondary_id>2015-002418-54</secondary_id>
    <secondary_id>U1111-1170-7054</secondary_id>
    <nct_id>NCT02911870</nct_id>
  </id_info>
  <brief_title>A Thorough QTc Trial Evaluating the Effect of SNAC on Cardiac Repolarisation in Healthy Male Subjects</brief_title>
  <official_title>A Thorough QTc Trial Evaluating the Effect of SNAC on Cardiac Repolarisation in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to evaluate the effect of SNAC
      on cardiac repolarisation in healthy male subjects
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment emergent adverse events</measure>
    <time_frame>From dosing (day 1) to follow-up (days 8-11)</time_frame>
    <description>PART A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The co-primary endpoints are Fridericia heart rate corrected QT interval (QTcF)</measure>
    <time_frame>At 10, 20, 30, 40, 50 minutes, 1, 1.5, 2, 2.5, 3, 4, 5, 8, and 12 hours</time_frame>
    <description>PART B</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed SNAC plasma concentration</measure>
    <time_frame>From 0 to 12 hours</time_frame>
    <description>PART A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trial population-specific (accounted for individual subject levels) corrected QT interval (QTcP)</measure>
    <time_frame>At 10, 20, 30, 40, 50 minutes, 1, 1.5, 2, 2.5, 3, 4, 5, 8 and 12 hours</time_frame>
    <description>PART B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the SNAC plasma concentration time curve</measure>
    <time_frame>From 0 to 12 hours</time_frame>
    <description>PART B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed SNAC plasma concentration</measure>
    <time_frame>From 0 to 12 hours</time_frame>
    <description>PART B</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A, SNAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 1.2mg, 2.4mg or 3.6mg increasing for each cohort of trial participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose at corresponding dose levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, SNAC, Placebo, Moxifloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 4 different treatments in random order. SNAC dose between 1.2-3.6 mg, Placebo in two different periods, moxifloxacin 400mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SNAC</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Part A, SNAC</arm_group_label>
    <arm_group_label>Part B, SNAC, Placebo, Moxifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Part A, placebo</arm_group_label>
    <arm_group_label>Part B, SNAC, Placebo, Moxifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Part B, SNAC, Placebo, Moxifloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male aged 18-55 years (both inclusive) at the time of signing informed consent

          -  Body mass index (BMI) between 18.5âˆ’28.0 kg/m^2 (both inclusive)

          -  Considered to be generally healthy based on the medical history, physical
             examination, and the results of vital signs and clinical laboratory tests performed
             during the screening visit, as judged by the investigator

          -  Normal electrocardiogram (ECG) at screening or minor findings considered not
             clinically significant, as judged by the investigator

        Exclusion Criteria:

          -  Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent
             per week), or subject smoking equal to or less than 5 cigarettes or the equivalent
             per week who is not able or willing to refrain from smoking and use of nicotine
             substitute products within 48 hours prior to each dosing and during the in-patient
             periods

          -  Any blood draw in excess of 25 mL in the past month, or donation of blood or plasma
             in excess of 400 mL within the 3 months preceding screening

          -  Sitting blood pressure at screening (after resting for at least 5 minutes) outside
             the range of 90-139 mmHg for systolic or 50-89 mmHg for diastolic

          -  History of major surgical procedures involving the stomach potentially affecting
             absorption of trial product (e.g. subtotal and total gastrectomy, sleeve
             gastrectomy,gastric bypass surgery)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <email>Clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 27, 2017</lastchanged_date>
  <firstreceived_date>September 20, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
